No Data
No Data
It is expected to open the first BNCT boron neutron treatment center in Hong Kong, and the Chinese Medicine Service (08037) wants to enter the Hong Kong-Shenzhen Science and Technology Innovation Park
The reason behind the memorandum of understanding with the Hong Kong-Shenzhen Science and Technology Innovation Park is a concrete reflection of China's biotechnology services speeding up the commercialization process of boron neutron capture therapy.
China Biotechnology Services (08037.HK) signs MOU with Hong Kong-Shenzhen Innovation and Technology Park
Gelonghui, April 18, 丨 China Biotechnology Service (08037.HK) announced that the Hong Kong-Shenzhen Innovation and Technology Park Limited (“Hong Kong-Shenzhen Innovation and Technology Park Corporation”) signed a memorandum of understanding with about 60 partner organizations (including companies), and held the Hong Kong-Shenzhen Innovation and Technology Park partner launch ceremony on April 18, 2024. According to the Memorandum of Understanding between the Company and Hong Kong-Shenzhen Innovation and Technology Park Corporation (collectively referred to as the “parties concerned”), the parties concerned have agreed (among others) to cooperate in the development of the Hong Kong-Shenzhen Innovation and Technology Park in the Lok Ma Chau Hetao area of the Hetao Shenzhen-Hong Kong Science and Technology Cooperation Zone. Development of boron neutron capture in cancer treatment
中國生物科技服務:2023 年報
China Biotechnology Services (08037) achieved revenue of approximately HK$212 million in 2023
China Biotechnology Services (08037) announced its 2023 results, with revenue of approximately HK$212 million and gross profit of 343...
CH BIOTECH SER: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
China Biotech Services (08037.HK) plans to place convertible bonds with a total principal amount of up to HK$88 million
Gelonghui, March 26, 丨 China Biotech Service (08037.HK) announced that on March 25, 2024, the company entered into a placement agreement with Guoyuan Finance (Hong Kong) Limited (as placement agent). According to this, the company has appointed an placement agent to distribute convertible bonds with a total principal amount of up to HK$88 million to no less than 6 undertakers. Such undertakers and their ultimate beneficial owners are independent third parties. Based on the initial exchange price of HK$0.55 per share, a maximum of 1.6 will be allotted and issued upon full exercise of the share conversion rights attached to the convertible bonds
No Data